Axonics Inc   (AXNX)
Other Ticker:  
Price: $57.0100 $0.32 0.564%
Day's High: $58.61 Week Perf: -1.42 %
Day's Low: $ 56.76 30 Day Perf: 15.17 %
Volume (M): 365 52 Wk High: $ 71.68
Volume (M$): $ 20,780 52 Wk Avg: $56.32
Open: $57.19 52 Wk Low: $47.59

 Market Capitalization (Millions $) 2,855
 Shares Outstanding (Millions) 50
 Employees 325
 Revenues (TTM) (Millions $) 342
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -94
 Capital Exp. (TTM) (Millions $) 3

Axonics Inc
Axonics Inc. is a medical technology company that develops and commercializes sacral neuromodulation systems for the treatment of urinary and bowel dysfunction. They are headquartered in Irvine, California, and operate globally.

Axonics' lead product, the Axonics Sacral Neuromodulation System, is a rechargeable implantable device that provides nerve stimulation to modulate the activity of the bladder and pelvic floor muscles. The device is implanted in the upper buttock area and connected to a lead that is positioned next to the sacral nerves. It is powered by a small, surgically-implanted battery that is designed to last up to 15 years. The device is controlled by a small, hand-held wireless programmer that allows patients to adjust the stimulation intensity and the frequency of the stimulation.

The Axonics system is designed to treat a range of clinical conditions, including overactive bladder, urinary retention, fecal incontinence, and chronic constipation. The system has been clinically proven to be safe and effective, with high success rates and low complication rates. Axonics received FDA approval in September 2019 for its sacral neuromodulation system for the treatment of patients with urinary dysfunction.

Axonics' mission is to provide patients suffering from urinary and bowel dysfunction with an alternative to traditional therapies such as medications and invasive surgeries. They focus on developing innovative technologies that are less invasive, more effective, and longer lasting than current treatments.

Axonics is committed to providing exceptional customer service and support to patients, healthcare providers, and their distribution partners. They have an experienced team of professionals dedicated to patient care and product development and are continuing to expand their global reach through regulatory approvals and partnerships.

   Company Address: 26 Technology Drive Irvine, 92618 CA
   Company Phone Number: 396-6322   Stock Exchange / Ticker: NASDAQ AXNX
   AXNX is expected to report next financial results on February 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Pavmed Inc

Pavmed Inc has failed to break-even despite the epic Surge in revenue in the financial time-frame ending September 30 2023

Pavmed Inc announced very solid Revenue improvement of 1103.947 % year on year to $0.92 million in the third quarter of 2023 earnings season, but lost money at $-0.16. Medical Equipment and Supplies company's business grew faster in contrast to the the revenue at nearly all of the Medical Equipment and Supplies industry contemporaries, in the third quarter of 2023 the two third entities in Medical Equipment and Supplies industries saw an average business improvement of 5.23% from the comparable reporting period a year ago.

Beyond Air Inc

The Medical Equipment and Supplies company announced Revenue of $0.239 million, in the July to September 30 2023

XAIR proclaimed $0.239 million, in Revenue in the financial period ending September 30 2023.

Sintx Technologies Inc

The company disclosed a quick revenue increase , in the financial span closing Sep 30 2023

For the third quarter of 2023 earnings season Sintx Technologies Inc increased a deficit per share of $-0.81 per share compare to $-0.11 a year prior and surged deficit from $-0.78 per share from the preceding reporting period. The revenue rose strongly by 59.155 % to $0.68 million from $0.43 million in the comparable reporting period a year prior and sequentially revenue surged by 33.465 % from $0.51 million. Medical Equipment and Supplies company's revenue, surge in the third quarter of 2023 compares advantageously to its Medical Equipment and Supplies sector contemporaries, which experienced all in all 5.23 % top-line elevation during the matching time yet.

Patterson Companies Inc

PDCO Reports Modest Revenue Rise, but Faces Steep Decline in Income in Latest Fiscal Period

Patterson Companies Inc, a leading player in the Medical Equipment and Supplies sector, recently released its financial results for the most recent fiscal period. Despite a modest revenue elevation of 1.588%, the company experienced a significant income contraction of -23.64% compared to the same quarter a year ago. This downturn in income can be attributed to various factors within the industry.
During the period in question, Patterson Companies Inc generated $1.65 billion in revenue and earnings per share (EPS) of $0.42. While these figures may seem promising, considering the growth in revenue and EPS, it is important to note that the company's performance lagged behind its sector peers. The Medical Equipment and Supplies sector witnessed a 5.93% rise in business during the second quarter of 2023, indicating that Patterson Companies Inc did not keep up with the industry's growth trajectory.

Embecta Corp

Embecta Corp Faces Significant Decline in Revenue During Fourth Quarter of 2023

Financial News Report:
Embecta Corp (NASDAQ: EMBC), a global diabetes care company, has reported a significant decline in income and profit for the July to September 2023 period. The company's income fell sharply by -92.65% to $0.10 per share compared to $1.42 per share in the same period last year. Additionally, profit plummeted by -59.89% from $0.26 per share in the prior quarter.
The revenue of Embecta Corp also went down sharply by -50.062% to $281.60 million from $563.90 million in the corresponding quarter a year prior. This is a sequential decrease of -1.366% from $285.50 million. In comparison, the rest of the Medical Equipment and Supplies sector posted a top-line growth in the fourth quarter of 2023.


Axonics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com